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A highly specific and sensitive radioimmunoassay (RIA) for a novel porcine brain natriuretic peptide (BNP) has been 
established to elucidate whether BNP-like immunoreactivity (LI) is present in human plasma. The antibody used was 
specific for BNP without any crossreactivities with known human atria1 natriuretic peptides (hANP). After extraction 
of human plasma with Sep-Pak cartridge, this assay allowed for detection of BNP-LI as low as 0.1 fmol/tube. In 12 
healthy subjects, the mean concentrations of plasma BNP-LI were 1.5 fmol/ml. Reverse-phase HPLC coupled with BNP 
RIA revealed that the single major component with BNP-LI, corresponding to porcine BNP(l-26) was apparently dis- 
tinct from that of a-hANP. These data indicate that a small molecular mass form with BNP-LI circulates in human blood. 
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1. INTRODUCTION 
Brain natriuretic peptide (BNP) has recently 
been isolated and sequenced from the extract of 
porcine brain [l]. Porcine (p) BNP consists of 26 
amino acid residues with a remarkable homology 
to, but definitely distinct from the sequence of 
atria1 natriuretic peptide (ANP). pBNP elicits a 
pharmacological spectrum of diuretic/natriuretic 
and hypotensive ffects very similar to that of ANP 
[l]. pBNP appears to interact with the same ANP 
receptor sites in rat vascular smooth muscle cells [2] 
and bovine adrenal glomerulosa cells [3]. Subse- 
quently, a large molecular mass BNP, designated 
as y-BNP [4], has been identified in the porcine 
cardiac atrium. y-BNP comprises 106 amino acid 
residues carrying BNP at its C-terminus, and serves 
as a possible precursor for BNP. It has recently 
been reported that a small molecular mass BNP is 
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secreted into the perfusate from the isolated por- 
cine heart [5]. These results suggest hat BNP is 
also synthesized by the heart and is secreted into 
the circulation in a similar fashion to ANP. How- 
ever, there has been no information available as to 
whether BNP circulates in human blood. There- 
fore, the present study was designed to establish a 
highly sensitive and specific radioimmunoassay 
(RIA) for BNP to measure concentrations of BNP- 
like immunoreactivity (LI) in normal human 
plasma, and to characterize the circulating form by 
reverse-phase HPLC. 
2. MATERIALS AND METHODS 
2.1. Production of antibody for pBNP 
Synthetic pBNP (Peptide Institute, Inc., Osaka, Japan) was 
conjugated to bovine thyroglobulin (Sigma Chemical, St. Louis, 
MO) using carbodiimide as a coupling agent. The conjugate 
emulsified with complete Freund’s adjuvant (Difco Labs, 
Detroit, MI) was injected intradermally at multiple sites on the 
back of Japanese white rabbits over a period of 12 weeks at 
3-14-day intervals. After repeated immunization, an antiserum 
suitable for RIA was obtained. 
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2.2. Iodination of pBNP 
pBNP was radioiodinated by the lactoperoxidase method. 
pBNP (12 fig) in 20 pl distilled water, 40 ~1 of 10 mM phosphate 
buffer, pH 5.6, 5 ~1 Na[“‘I] (1 mCi, New England Nuclear, 
Boston, MA), 0.624 pg lactoperoxidase (Sigma Chemical, St. 
Louis, MO) in 5 ~1 phosphate buffer, and 10 ~1 of 1.8 mM Hz02 
were added sequentially. The reaction was allowed to proceed 
for 30 min at room temperature, and terminated by the addition 
of 50~1 of 50 mM mercaptoethanol. Labeled pBNP was 
purified by using reverse-phase HPLC. The specific activity of 
[‘?]BNP ranged from 510 to 600 &i/pg. 
2.3. RM of BNP 
RIA for BNP was performed essentially as reported for ANP 
RIA [6]. In brief, 0.1 ml sample or standard, 0.1 ml assay buf- 
fer and 0.1 ml anti-BNP-serum (final dilution, 1: 420 000) were 
incubated at 4°C for 24 h, followed by the addition of 0.05 ml 
[“‘I]BNP (approx. 10000 cpm) and further incubation at 4°C 
for 24 h. The bound ligands were separated from free ligands by 
the double antibody method. The standard curve was con- 
structed using B/B0 vs pBNP standard. The amount,of BNP in 
the unknown samples was extrapolated from the standard curve 
linearized by a logit-log transformation. 
2.4. Plasma extraction 
2 ml aliquot of human plasma acidified with trifluoroacetic 
acid (TFA) was applied to a Sep-Pak Cis cartridge (Waters, 
Milford, MA) prewashed sequentially with methanol, distilled 
water and 0.09% TFA. The material(s) absorbed to the car- 
tridge was eluted with 2 ml of 60% acetonitrile/0.09% TFA and 
evaporated. The dried residues were reconstituted in the assay 
buffer and subjected to RIA for BNP and (r-ANP [6]. For 
chromatographic analysis of plasma BNP-LI, an aliquot of 
human plasma extract was subjected to reverse-phase HPLC. 
2.5. Reverse-phase HPLC 
Reverse-phase HPLC was performed using an octadecyl-silica 
column (0.45 x 25 cm, Jasco, Tokyo, Japan) eluted with a 
linear gradient of acetonitrile from 15% to 60% in 0.09% TFA 
for 1 h with a flow rate of 1 ml/min. l-ml fractions were col- 
lected and assayed for BNP-LI and cY-hANP-LI. 
3. RESULTS 
As shown in fig.1, the minimum detectable 
quantity of pBNP was 0.1 fmolkube (99070 con- 
fidence), and the 50% binding intercept was 
1.5 fmolkube. The intra- and inter-assay coeffi- 
cients of variation (n = 5) were 6 and lo%, respec- 
tively. The antibody crossreacted less than 0.001% 
with cu-hANP, &hANP, y-hANP and rat a-ANP 
on a molar basis (fig.2); it had no crossreactivities 
with angiotensin II or arginine-vasopressin. The 
dilution curves generated by human plasma ex- 
tracts were parallel to that of standard pBNP 
(fig. 1). The recovery of unlabeled pBNP added to 
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Fig.1. Radioimmunoassay for BNP. Standard curve for 
pBNP($: mean + SD, n = 4) and dilution curves of normal 
human plasma extracts (O,O) are shown. Serial dilutions of the 
human plasma extracts are denoted in the upper panel. 
out the extraction procedure. In 12 normal subjects 
(7 males and 5 females, aged 28.3 k 9.6 year-old), 
the mean concentrations of BNP-LI and a-hANP- 
LI were 1.5 f 0.4 fmol/ml and 5.8 k 1.7 fmol/ml, 
respectively. 
Elution profiles of BNP and a-hANP-LI in 
human plasma extract by reverse-phase HPLC are 
shown in fig.3. A single major component with 
BNP-LI coeluting with authentic pBNP(l-26) was 
observed (fig.3, upper panel), while one major 
component with a-hANP-LI corresponding to the 
position of authentic cu-hANP(l-28) was eluted 
earlier than pBNP (fig.3, lower panel). 
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Fig.2. Crossreactivities of ANP and related peptides in BNP 
RIA. Serial dilution curves of pBNP(l-26) (o), cy-hANP (A), & 
hANP (0), y-hANP (n), and cu-rat ANP (A) are shown. 
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Fig.3. Reverse-phase HPLC profiles of BNP- and cu-hANP-LI 
in human plasma extract. An aliquot of human plasma extract 
(3.5 ml) was subjected to a reverse-phase HPLC. Concentra- 
tions of BNP-LI (upper panel) and m-hANP-LI (lower panel) 
are shown by the solid columns. Arrows indicate the elution 
positions of cu-hANP(l), pBNP(2) and y-hANP(3), respectively. 
A linear gradient of acetonitrile from 15 to 60% is denoted by 
solid lines. 
4. DISCUSSION 
By using sensitive and specific RIA for BNP with 
a minimum detectable dose of 0.1 fmol of pBNP, 
we were able to measure BNP-LI in normal human 
plasma. The antibody used in the present RIA was 
specific for pBNP without any crossreactivities 
with structurally similar hANP family, including 
cY-hANP, &hANP and y-hANP. pBNP shows a 
remarkable sequence homology to ANP (70%), 
but has 7 amino acid replacements and one inser- 
tion compared to Lu-hANP(4-28) [ 11. Therefore, it 
is suggested that the principal antigenic determi- 
nant of the antibody is directed toward the residues 
not shared by the hANP molecule. 
Dilution curves of human plasma extracts ap- 
pear to be parallel to that of standard pBNP, sug- 
gesting that the material(s) immunologically in- 
distinguishable from pBNP is present in human 
plasma. We have also observed significant 
amounts of BNP-LI in the human atrial tissues, but 
not in the ventricular tissues (unpublished). Al- 
though the complete amino acid structure of 
human BNP is not determined yet, our data strong- 
ly suggest hat BNP structurally very similar, if not 
identical, to pBNP is also present in human plasma 
and heart. 
Plasma concentrations of BNP-LI in normal 
subjects (1.5 fmol/ml) are comparable to those of 
porcine plasma (1.4 fmol/ml) [3], but about 4-fold 
lower than those of a-hANP-LI. 
Reverse-phase HPLC coupled with RIAs for 
BNP and cu-hANP revealed that BNP-LI in human 
plasma consisted of only one major component 
with identical retention time to that of authentic 
pBNP(l-26), apparently distinct from that of (Y- 
hANP-LI, suggesting that BNP is more hydro- 
philic in nature than a-hANP. These data are also 
consistent with those of a recent report [5] in which 
the major BNP-LI in the perfusate of the isolated 
porcine atrium is a small molecular mass compo- 
nent corresponding to authentic pBNP. Taken to- 
gether, it is suggested that the main secretory and 
circulatory form of BNP in pigs and man is a small 
molecular mass component in analogy to a-hANP. 
It remains to be determined whether the circulating 
BNP-LI in human plasma derives mainly from the 
human heart and whether BNP and ANP are co- 
secreted under physiological and pathological con- 
ditions. 
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